Billion-dollar backstop
Name: David Mott Title:
General Partner at New Enterprise Associates
Billions at his disposal paired with a broad, deep swath of biotech experience make David Mott a key industry figure. Mott has been with NEA since September 2008 and heads up its biopharma investment. Healthcare typically claims $750 million to $1 billion, or 30% to 40%, of each NEA fund; the firm also invests in information technology.
{iframe}http://www.fiercebiotech.com/special-reports/influentials-2015-david-mott-new-enterprise-associates{/iframe}